Nacolomab tafenatox

Drug Profile

Nacolomab tafenatox

Alternative Names: C242 Fab-SEA; LS 4565; PNU 214565; PNV 214565

Latest Information Update: 06 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Developer Nonindustrial source; Pharmacia Corporation
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 23 Mar 2000 A phase I study in patients with colorectal and pancreatic cancers has been added to the therapeutic trials and adverse events sections
  • 24 Sep 1998 A study has been added to the therapeutics trials and immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top